Haemonetics (NYSE:HAE) Sets New 52-Week Low - Should You Sell?

Haemonetics Co. (NYSE:HAE - Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $66.08 and last traded at $66.83, with a volume of 53532 shares trading hands. The stock had previously closed at $69.05.

Wall Street Analyst Weigh In

HAE has been the topic of several recent research reports. JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective on the stock. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective for the company in a research report on Friday, November 8th. Needham & Company LLC restated a "buy" rating and set a $112.00 target price on shares of Haemonetics in a research report on Tuesday, December 3rd. Finally, Barrington Research restated an "outperform" rating and issued a $108.00 price target on shares of Haemonetics in a research report on Wednesday, December 4th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $108.78.

Haemonetics Stock Performance

The company has a market cap of $3.16 billion, a P/E ratio of 26.12, a PEG ratio of 1.07 and a beta of 0.39. The firm has a 50 day moving average of $77.44 and a 200-day moving average of $78.73. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently added to or reduced their stakes in HAE. Creative Planning purchased a new stake in Haemonetics during the second quarter valued at approximately $368,000. Handelsbanken Fonder AB increased its stake in shares of Haemonetics by 23.9% in the third quarter. Handelsbanken Fonder AB now owns 17,095 shares of the medical instruments supplier's stock worth $1,374,000 after acquiring an additional 3,300 shares during the period. Dynamic Advisor Solutions LLC raised its stake in shares of Haemonetics by 10.1% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 20,154 shares of the medical instruments supplier's stock valued at $1,620,000 after buying an additional 1,848 shares during the last quarter. West Coast Financial LLC lifted its holdings in Haemonetics by 2.2% in the third quarter. West Coast Financial LLC now owns 47,182 shares of the medical instruments supplier's stock valued at $3,792,000 after acquiring an additional 1,013 shares during the period. Finally, Inspire Investing LLC boosted its holdings in Haemonetics by 19.7% during the third quarter. Inspire Investing LLC now owns 5,130 shares of the medical instruments supplier's stock worth $412,000 after buying an additional 845 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.